Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Levothyroxine-induced Hyperthyroidism on Sorafenib PK
NCT02332031Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sorafenib in thyroid cancer, renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoint: Area under the concentration vs. time curve from zero to infinity. Started Feb 2015; status: completed.
02
Drugs
sorafenib
03
Conditions
thyroid cancerrenal cell carcinoma (RCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02332031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332031.